建发合诚：10月24日召开董事会会议

Group 1 - The core point of the article is that Jianfa Hecheng held its sixth board meeting on October 24, 2025, to discuss amendments to corporate governance systems [1] - For the fiscal year 2024, Jianfa Hecheng's revenue composition is as follows: reinforcement business accounts for 89.41%, service industry for 10.27%, manufacturing for 0.26%, and other businesses for 0.06% [1] - As of the report date, Jianfa Hecheng has a market capitalization of 3.1 billion yuan [1] Group 2 - The article highlights that Chinese innovative drugs have generated $80 billion in overseas licensing this year [1] - It features an interview with Lu Gang, a partner at Chuangdong Investment, discussing the hot secondary market in biomedicine and the cooling fundraising in the primary market [1]